Valuation: Orexo AB

Market Cap 444M 44.99M 39.32M 36.95M 33.72M 63.29M 4.3B 63.3M 171M 2.2B 169M 165M 7.08B P/E 2026 *
-1.21x
P/E 2027 * -1.74x
Enterprise Value 339M 34.34M 30.01M 28.2M 25.74M 48.31M 3.28B 48.32M 131M 1.68B 129M 126M 5.4B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 16.4x
Free-Float
78.37%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week-2.63%
Current month-19.75%
1 month-5.97%
3 months-42.73%
6 months-43.88%
Current year-58.14%
1 week 12.2
Extreme 12.2
13.22
1 month 12.2
Extreme 12.2
16.6
Current year 12.2
Extreme 12.2
36
1 year 12.2
Extreme 12.2
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/25 Buy

Chief Executive Officer

6 0.0000%
9/4/25 Free

Chief Executive Officer

1,393 0.0040%
9/3/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-2.63%-55.63%-29.61% 45.1M
+1.46%+5.89%+89.38%+43.18% 369B
+0.41%+1.72%+21.88%-16.36% 66.12B
+1.92%+6.86%+45.04%+186.92% 12.65B
-0.29%+1.37%-4.00%-15.28% 7.5B
-0.90%-2.78%-32.25%-11.61% 4.42B
-0.66%-5.06%-36.68%+7.73% 4.1B
+2.65%+8.52%-24.38%-5.99% 3.1B
+1.80%+5.39%-7.40%+54.44% 2.49B
+0.11%+2.65%-21.37%-33.32% 1.98B
Average +0.64%+1.60%-2.54%+18.01% 47.13B
Weighted average by Cap. +1.29%+2.90%+73.25%+36.34%

Financials

2026 *2027 *
Net sales 19M 1.93M 1.68M 1.58M 1.44M 2.71M 184M 2.71M 7.33M 94.1M 7.24M 7.08M 303M 27M 2.74M 2.39M 2.25M 2.05M 3.85M 262M 3.85M 10.42M 134M 10.29M 10.06M 431M
Net income -375M -38.04M -33.24M -31.25M -28.51M -53.51M -3.64B -53.52M -145M -1.86B -143M -140M -5.99B -
Net Debt -105M -10.65M -9.31M -8.75M -7.98M -14.98M -1.02B -14.99M -40.52M -520M -40M -39.12M -1.68B -
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
26-09-22 SEK 12.60 -0.79% 52,276
26-09-21 SEK 12.70 -0.78% 38,675
26-09-18 SEK 12.80 -0.31% 20,269
26-09-17 SEK 12.84 +0.78% 10,200
26-09-16 SEK 12.74 -1.55% 23,102
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!